Sickle Cell Disease - Revision history

WikiSysop at 01:03, 6 March 2026

2026-03-06T01:03:19Z

← Older revision		Revision as of 01:03, 6 March 2026
Line 77:		Line 77:

	[https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-025-01479-3 Guidelines for the management of emergencies and critical illness in pediatric and adult patients with sickle cell disease]		[https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-025-01479-3 Guidelines for the management of emergencies and critical illness in pediatric and adult patients with sickle cell disease]

			Tan Y, Kashyap Y, De La Toba E, Croslow SW, Gill M, Guo X, Ilktach G, Davy E, Molokie R, Wang ZJ et al: Hemorphins, atypical endogenous opiate peptides, in sickle cell disease and their association with pain. Pain 2026, 167(2):326–337.

			Argueta DA, Gupta K: New kid on the block: hemorphins in sickle cell disease. Pain 2026, 167(2):249–250.

			Mielczarek P, Hartman K, Drabik A, Hung HY, Huang EY, Gibula-Tarlowska E, Kotlinska JH, Silberring J: Hemorphins-From Discovery to Functions and Pharmacology. Molecules 2021, 26(13).

			Lei J, Benson B, Tran H, Ofori-Acquah SF, Gupta K: Comparative Analysis of Pain Behaviours in Humanized Mouse Models of Sickle Cell Anemia. PloS one 2016, 11(8):e0160608.

WikiSysop at 06:01, 31 May 2025

2025-05-31T06:01:54Z

← Older revision		Revision as of 06:01, 31 May 2025
Line 75:		Line 75:

	[https://onlinelibrary.wiley.com/doi/10.1002/pbc.31458 Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle Cell Vaso-Occlusive Pain]		[https://onlinelibrary.wiley.com/doi/10.1002/pbc.31458 Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle Cell Vaso-Occlusive Pain]

			[https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-025-01479-3 Guidelines for the management of emergencies and critical illness in pediatric and adult patients with sickle cell disease]

WikiSysop at 12:29, 19 January 2025

2025-01-19T12:29:03Z

← Older revision		Revision as of 12:29, 19 January 2025
Line 73:		Line 73:

	"First Patient Begins Newly Approved Sickle Cell Gene Therapy." The New York Times, May 6, 2024.		"First Patient Begins Newly Approved Sickle Cell Gene Therapy." The New York Times, May 6, 2024.

			[https://onlinelibrary.wiley.com/doi/10.1002/pbc.31458 Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle Cell Vaso-Occlusive Pain]

WikiSysop at 15:28, 16 October 2024

2024-10-16T15:28:13Z

← Older revision		Revision as of 15:28, 16 October 2024
Line 53:		Line 53:

	Delatte SJ, Hebra A, Tagge EP, Jackson S, Jacques K, Othersen HB Jr. Acute chest syndrome in the postoperative sickle cell patient. J Pediatr Surg. 1999 Jan; 34(1): 188-91; discussion 191-2. PMID: 10022169		Delatte SJ, Hebra A, Tagge EP, Jackson S, Jacques K, Othersen HB Jr. Acute chest syndrome in the postoperative sickle cell patient. J Pediatr Surg. 1999 Jan; 34(1): 188-91; discussion 191-2. PMID: 10022169

			Sohn E. Ease the Pain: The excruciating pain of sickle cell disease is difficult to prevent or treat. Researchers are working on new ways to provide relief. Sci Am 2024; 331(3): 94.

			Reardon S. New Treatments for Sickle Cell Disease: After years of little progress, new therapies to treat or even cure the disease are reaching patients. Sci Am 2024; 331(3): 85.

			Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Annals of internal medicine 2008; 148(2): 94-101.

			Smith WR, Scherer M. Sickle-Cell Pain: Advances in Epidemiology and Etiology. Hematology 2010; 2010(1): 409-15.

			Dampier C, Ely E, Brodecki D, O'Neal P. Home management of pain in sickle cell disease: a daily diary study in children and adolescents. J Pediatr Hematol Oncol 2002; 24(8): 643-7.

			Brandow AM, Brousseau DC, Panepinto JA. Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. Br J Haematol 2009; 144(5): 782-8.

			Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol 2005; 79(1): 17-25.

			Dampier CD, Telen MJ, Wun T, et al. A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis. Blood 2023; 141(2): 168-79.

			Karimi M, Bahadoram M, Mafakher L, Rastegar M. Impact of Imatinib on reducing the painful crisis in patients with sickle cell disease. Hematol Transfus Cell Ther 2024; 46(4): 387-92.

			"First Patient Begins Newly Approved Sickle Cell Gene Therapy." The New York Times, May 6, 2024.

WikiSysop at 17:49, 21 August 2024

2024-08-21T17:49:47Z

← Older revision		Revision as of 17:49, 21 August 2024
Line 49:		Line 49:

	10. Pignatti M, Zanella S, Borgna-Pignatti C. Can the surgical tourniquet be used in patients with sickle cell disease or trait? A review of the literature. Expert Rev Hematol 2017;10(2):175-182. (In eng). DOI: 10.1080/17474086.2017.1273765.		10. Pignatti M, Zanella S, Borgna-Pignatti C. Can the surgical tourniquet be used in patients with sickle cell disease or trait? A review of the literature. Expert Rev Hematol 2017;10(2):175-182. (In eng). DOI: 10.1080/17474086.2017.1273765.

			Howard J, Hart N, Roberts-Harewood M, et al. Guideline on the management of acute chest syndrome in sickle cell disease. Br J Haematol. 2015 May; 169(4): 492-505. PMID: 25824256

			Delatte SJ, Hebra A, Tagge EP, Jackson S, Jacques K, Othersen HB Jr. Acute chest syndrome in the postoperative sickle cell patient. J Pediatr Surg. 1999 Jan; 34(1): 188-91; discussion 191-2. PMID: 10022169

WikiSysop at 17:07, 15 July 2024

2024-07-15T17:07:26Z

← Older revision		Revision as of 17:07, 15 July 2024
Line 29:		Line 29:

	[https://www.apsf.org/article/preoperative-transfusion-and-sickle-cell-disease-in-the-pediatric-patient/ APSF: Preoperative Transfusion and Sickle Cell Disease in the Pediatric Patient]		[https://www.apsf.org/article/preoperative-transfusion-and-sickle-cell-disease-in-the-pediatric-patient/ APSF: Preoperative Transfusion and Sickle Cell Disease in the Pediatric Patient]

			Firth PG, McMillan KN, Haberkern CM, Yaster M, Bender MA, Goodwin SR. A survey of perioperative management of sickle cell disease in North America. PaediatrAnaesth 2011;21(1):43-49.

			2. Goodwin SR, Haberkern C, Crawford M, Lerman J, Mancuso T, Yaster M. Sickle cell and anesthesia: do not abandon well-established practices without evidence. Anesthesiology 2005;103(1):205-207.

			3. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group [see comments]. NEnglJMed 1995;333(4):206-213.

			4. Azbell RCG, Lanzkron SM, Desai PC. Current Evidence and Rationale to Guide Perioperative Management, Including Transfusion Decisions, in Patients With Sickle Cell Disease. Anesthesia and analgesia 2023;136(6):1107-1114. (In eng). DOI: 10.1213/ane.0000000000006463.

			5. Baijal RG, Dalal PG, Kanjia M. Preoperative Transfusion and Sickle Cell Disease in the Pediatric Patient. Anesthesia Patient Safety Foundation. 06/2024 (https://www.apsf.org/article/preoperative-transfusion-and-sickle-cell-disease-in-the-pediatric-patient/?utm_source=APSF+Newsletter+Email+-+External&utm_medium=email&utm_campaign=EMAIL_CAMPAIGN_2024_06_01).

			6. Hyder O, Yaster M, Bateman BT, Firth PG. Surgical procedures and outcomes among children with sickle cell disease. Anesthesia and analgesia 2013;117(5):1192-6. (In eng). DOI: 10.1213/ANE.0b013e3182a44d74.

			7. Waldron P, Pegelow C, Neumayr L, et al. Tonsillectomy, adenoidectomy, and myringotomy in sickle cell disease: perioperative morbidity. Preoperative Transfusion in Sickle Cell Disease Study Group. JPediatrHematolOncol 1999;21(2):129-135.

			8. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 2020;4(2):327-355. (In eng). DOI: 10.1182/bloodadvances.2019001143.

			9. Salvi PS, Solomon DG, Cowles RA. Preoperative Transfusion and Surgical Outcomes for Children with Sickle Cell Disease. J Am Coll Surg 2022;235(3):530-538. (In eng). DOI: 10.1097/xcs.0000000000000267.

			10. Pignatti M, Zanella S, Borgna-Pignatti C. Can the surgical tourniquet be used in patients with sickle cell disease or trait? A review of the literature. Expert Rev Hematol 2017;10(2):175-182. (In eng). DOI: 10.1080/17474086.2017.1273765.

WikiSysop at 14:19, 5 July 2024

2024-07-05T14:19:03Z

← Older revision		Revision as of 14:19, 5 July 2024
Line 27:		Line 27:

	Kinney TR, Ware RE, Schultz WH, Filston HC. Long-term management of splenic sequestration in children with sickle cell disease. J Pediatr. 1990 Aug; 117(2 Pt 1): 194-9. PMID: 2380816		Kinney TR, Ware RE, Schultz WH, Filston HC. Long-term management of splenic sequestration in children with sickle cell disease. J Pediatr. 1990 Aug; 117(2 Pt 1): 194-9. PMID: 2380816

			[https://www.apsf.org/article/preoperative-transfusion-and-sickle-cell-disease-in-the-pediatric-patient/ APSF: Preoperative Transfusion and Sickle Cell Disease in the Pediatric Patient]

WikiSysop at 18:38, 6 July 2023

2023-07-06T18:38:35Z

← Older revision		Revision as of 18:38, 6 July 2023
Line 21:		Line 21:

	[https://pubmed.ncbi.nlm.nih.gov/36031024/ Special issue: Pediatric pain and sickle cell disease]		[https://pubmed.ncbi.nlm.nih.gov/36031024/ Special issue: Pediatric pain and sickle cell disease]

			Brousse V, Elie C, Benkerrou M, et al. Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients. Br J Haematol. 2012 Mar; 156(5): 643-8. PMID: 22224796

			Al-Salem AH. Splenic complications of sickle cell anemia and the role of splenectomy. ISRN Hematol. 2011; 2011: 864257. PMID: 22084706

			Kinney TR, Ware RE, Schultz WH, Filston HC. Long-term management of splenic sequestration in children with sickle cell disease. J Pediatr. 1990 Aug; 117(2 Pt 1): 194-9. PMID: 2380816

WikiSysop at 13:07, 5 June 2023

2023-06-05T13:07:48Z

← Older revision		Revision as of 13:07, 5 June 2023
Line 9:		Line 9:

	__NOTOC__ __NOEDITSECTION__		__NOTOC__ __NOEDITSECTION__

			[https://pubmed.ncbi.nlm.nih.gov/37205803/ Current Evidence and Rationale to Guide Perioperative Management, Including Transfusion Decisions, in Patients With Sickle Cell Disease]

	[[The anaesthetic management of children with sickle cell disease]]		[[The anaesthetic management of children with sickle cell disease]]

WikiSysop at 17:53, 27 September 2022

2022-09-27T17:53:27Z

← Older revision		Revision as of 17:53, 27 September 2022
Line 12:		Line 12:
	[[The anaesthetic management of children with sickle cell disease]]		[[The anaesthetic management of children with sickle cell disease]]

	https://www.nejm.org/doi/full/10.1056/NEJM199507273330402		[https://www.nejm.org/doi/full/10.1056/NEJM199507273330402 A Comparison of Conservative and Aggressive Transfusion Regimens in the Perioperative Management of Sickle Cell Disease]

	https://pubs.asahq.org/anesthesiology/article/101/3/766/9209/Sickle-Cell-Disease-and-Anesthesia		[https://pubs.asahq.org/anesthesiology/article/101/3/766/9209/Sickle-Cell-Disease-and-Anesthesia Sickle Cell Disease and Anesthesia]

	https://www.bjaed.org/article/S2058-5349(18)30103-3/fulltext		[https://www.bjaed.org/article/S2058-5349(18)30103-3/fulltext Anaesthetic management of children with sickle cell disease]

			[https://pubmed.ncbi.nlm.nih.gov/36031024/ Special issue: Pediatric pain and sickle cell disease]